Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors
暂无分享,去创建一个
Soldano Ferrone | Vikram Deshpande | Mark Vangel | Andrew L. Warshaw | K. Lillemoe | M. Vangel | J. Wargo | D. Ting | M. Ligorio | V. Deshpande | S. Ferrone | A. Warshaw | C. Ferrone | Jennifer Wargo | Matteo Ligorio | Cristina R. Ferrone | Keith D. Lillemoe | Carlos Fernández-del Castillo | David T. Ting | F. Sabbatino | Vincenzo Villani | Krishnan K. Mahadevan | Francesco Sabbatino | Irene Zhang | V. Villani | C. Fernandez-del Castillo | I. Zhang | C. F. Fernandez-Del Castillo
[1] L. Gullo,et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study , 2003, American Journal of Gastroenterology.
[2] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[3] A. Scarpa,et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. , 2012, Journal of the National Cancer Institute.
[4] G. Petersen,et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] C. Allis,et al. Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[6] S. Ferrone,et al. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] M. Nasr,et al. Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2008, The American Journal of dermatopathology.
[8] H Stein,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.
[9] F. Bosman,et al. WHO Classification of Tumours of the Digestive System , 2010 .
[10] William Mantovani,et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients , 2010, Modern Pathology.
[11] Ben Lawrence,et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.
[12] J. Chabot,et al. Nonfunctional pancreatic neuroendocrine tumors. , 2014, The Surgical clinics of North America.
[13] F. Gao,et al. Comparison of WHO Classifications (2004, 2010), the Hochwald Grading System, and AJCC and ENETS Staging Systems in Predicting Prognosis in Locoregional Well-differentiated Pancreatic Neuroendocrine Tumors , 2013, The American journal of surgical pathology.
[14] Caterina Giannini,et al. Assessment and Prognostic Significance of Mitotic Index Using the Mitosis Marker Phospho-histone H3 in Low and Intermediate-grade Infiltrating Astrocytomas , 2006, The American journal of surgical pathology.
[15] Diane D. Liu,et al. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. , 2011, Lung cancer.
[16] Parvez M Lokhandwala,et al. Mitotic Count by Phosphohistone H3 Immunohistochemical Staining Predicts Survival and Improves Interobserver Reproducibility in Well-differentiated Neuroendocrine Tumors of the Pancreas , 2015, The American journal of surgical pathology.
[17] Teresa Ribalta,et al. The Mitosis-Specific Antibody Anti-Phosphohistone-H3 (PHH3) Facilitates Rapid Reliable Grading of Meningiomas According to WHO 2000 Criteria , 2004, The American journal of surgical pathology.
[18] L. Yip,et al. Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients , 2010, Journal of Gastrointestinal Surgery.
[19] C. Ko,et al. Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients , 2008, Annals of surgery.
[20] V. Sondak,et al. Use of Anti-phosphohistone H3 Immunohistochemistry to Determine Mitotic Rate in Thin Melanoma , 2010, The American Journal of dermatopathology.
[21] R. Hruban,et al. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy , 2012, Nature Reviews Gastroenterology &Hepatology.
[22] Laura H. Tang,et al. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues. , 2013, Seminars in diagnostic pathology.
[23] Toby C. Cornish,et al. Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate , 2013, The American journal of surgical pathology.